Ahluwalia and Hobbs AJ. Endothelium-derived c-type natriuretic peptide more than just a hyperpolarized factor. Trends Pharmacol Sci, 26:162–167, 2005.
Ahluwalia, MacAllister RJ, and Hobbs AJ. Vascular actions of natriuretic peptides. cyclic gmp-dependent and -independent mechanisms. Basic Res Cardiol, 99:83–89, 2004.
Allgren RL, TC Marbury TC, SN Rahman, LS Weisberg, AZ Fenves, RA Lafayette, RM Sweet, FC Genter, BR Kurnik, JD Conger, and MH Sayegh. Anaritide in acute tubular necrosis; auriculin anaritide acute renal failure study group. N Engl J Med, 336:828–834, 1997.
Anand, Fisher, Chiang, and et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (val-heft). Circulation, 107:1278–83, 2003.
Andreassi, Del Ry S, and Palmieri C et al. Up-regulation of ‘clearance’ receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail, 3:407–414, 2001.
Arora RR, Venkatesh PK, Molnar J.  Short and long-term mortality with nesiritide.  Am Heart J. 2006;152(6):1084.
Attaran S, Sherwood R, Desai J, Langworthy R, Mhandu R, John L, El-Gamel A.  Brain natriuretic peptide a predictive marker in cardiac surgery. Interactive CardioVascular and Thoracic Surgery 2009, 9:662–666
Baig M, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Am Heart J 1998; 135:S217.
Bartels, H Bukulmez, P Padayatti, DK Rhee, C van RavenswaaijArts, RM Pauli, S Mundlos, D Chitayat, LY Shih, LI Al-Gazali, S Kant, T Cole, J Morton, V Cormier-Daire, L Faivre, M Lees, J Kirk, GR Mortier, J Leroy, B Zabel, CA Kim, Y Crow, NE Braverman, F van-den Akker, and MLA Warman. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type maroteaux. Am J Hum Genet, 75:27–34, 2004.
Baruch, Glazer RD, and Aknay N et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (valheft). Am Heart J, 148:951–957, 2004.
Bayes-Genis, Barallat, and Richards. A test in context. Neprilysin: function, inhibition and biomarker. J Am Coll Cardiol, 68:639–53, 2016.
Bayes-Genis, Lloyd-Jones, van Kimmenade, and et al. Effect of body mass index on diagnostic and prognostic usefulness of amino- terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med, 167:400–7, 2007. 
Beck da Silva, de Bold A, and Fraser M et al. Bnp-guided therapy not better than expert’s clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail, 11:248–253, 2005.
Belenky, Smith, and Zhang. The effect of class-specific protease inhibitors on the stabilization of b-type natriuretic peptide in human plasma. Clin Chim Acta, 340:163–172, 2004.
Berger, M Huelsman, K Strecker, A Bojic, P Moser, B Stanek, and R Pacher. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 105:2392–7, 2002.
Bettencourt, Ferreira, Azevedo, and et al. Preliminary data on the potential usefulness of b-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med, 113, 2002.
Bettencourt. Nt-probnp and bnp: biomarkers for heart failure management. (Review) Eur J Heart Fail, 6:359–363, 2004. 
Bhardwaj A, Januzzi JL Jr. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit Pathw Cardiol 2009; 8:146.
Booz. Putting the brakes on cardiac hypertrophy exploiting the no- cGMP counter-regulatory system. Hypertension, 45:341–346, 2005.
Bruins, MR Fokkema, JW Romer, MJ Dejongste, FP van der Dijs, JM van den Ouweland, and FA Muskiet. High intraindividual variation of b-type natriuretic peptide (bnp) and amino-terminal probnp in patients with stable chronic heart failure. Clin Chem, 50:2052–8, 2004.
Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38(15):1132.
Carubelli V, Lombardi C, Lazzarini V, et al. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. J Cardiovasc Med (Hagerstown) 2016; 17:828.
Cerrahoglu M, Iskesen I, Tekin C, Onur E, Yildirim F, Sirin BH.  N-terminal proBNP level scan predict cardiac failure after cardiac surgery.  Circulation Journal 2007, 71:79-83.
Charles, TC Prickett, EA Espiner, MT Rademaker, AM Richards, and TG Yandle. Regional sampling and the effects of experimental heart failure in sheep: differential responses in a, b and c-type natriuretic peptides. Peptides, 27:62–68, 2006.
Charloux, Piquard F, and Doutreleau S et al. Mechanisms of renal hyporesponsiveness to anp in heart failure. (Review) Eur J Clin Invest, 33:769–778, 2003.
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM, NHLBI Heart Failure Clinical Research Network.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.  JAMA. 2013;310(23):2533
Cheng, Kazanagra, Garcia, and et al. A rapid bedside test for b- type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol, 37: 386–91, 2001.
Clerico and Emdin. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. (Review) Clin Chem, 50:33–50, 2004.
Clerico, Del Ry S, and Maffei S et al. Circulating levels of cardiac natriuretic hormones in healthy adult subjects: effects of aging and sex. Clin Chem Lab Med, 40:371–377, 2002.
Clerico, Iervasi G, and Pilo A. Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab, 1:85–105, 2000.
Clerico, Zucchelli GC, Pilo A, and Emdin M. Clinical relevance of biological variation of b-type natriuretic peptide. (Letter) Clin Chem, 51:925–926, 2005.
Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246.
Cowie and Mendez GF. Bnp and congestive heart failure. (Review) Prog Cardiovasc Dis, 44:293–321, 2002.
Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, and G Francis. Clinical applications of b-type natriuretic peptide (bnp) testing. Eur Heart J, 24:1710–8, 2003.
Cuthbertson BH, Croal BL, Rae D, Gibson PH, McNeilly JD, Jeffrey RR, Cairns Smith W, Prescott GJ, Buchan KG, El-Shafei H, Gibson GA and Hillis GS.  N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study.  Br J Anaesth 2009; 103: 647–53
Daniels and AS Maisel. natriuretics peptides. Journal of American College of Cardiology, 50:2357–68, 2007. 
Daniels, Clopton, and Bhalla et al. How obesity affects the cut-points for b-type natriuretic peptide in the diagnosis of acute heart failure. results from the breathing not properly multinational study. Am Heart J, 151:999–1005, 2006.
De Filippi, van Kimmenade, and Pinto. Amino- erminal pro-b-type natriuretic peptide testing in renal disease. Am J Cardiol, 101:82– , 2008.
De Lissovoy, DM Stier, G Ciesla, M Munger, and AJ Burger. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol, 92:631–633, 2003. 
Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJ, Solomon SD, PARADIGM-HF Investigators. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016;68(3):241. 
Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD.  Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.  Eur Heart J. 2015;36(30):1990. Epub 2015 May 28. 
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019 
Dickey, DR Flora, PM Bryan, X Xu, Y Chen, and LR Potter. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (npr)-b, not npr-a, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology, 148:35183522, 2007.
Doust, Glasziou PP, Pietrzak E, and Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. (Review) Arch Intern Med, 164:1978–1984, 2004. 
Doust, Pietrzak E, Dobson A, and Glasziou P. How well does b-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. (Review) BMJ, 330:625–633, 2005.
Eliasdottir SB, Klemenzson G, Torfason B, Valsson F.  Brian natriuretic peptide is a good predictor for outcome in cardiac surgery.  Acta Anaesthesiol Scan 2008, 52:182-187
Emdin, Passino C, and Prontera C et al. Cardiac natriuretic hormones, neuroormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med, 42:627–636, 2004.
Evans, Youssef, and Yandle TG. Effects of endothelin-1 on release of adrenomedullin and c-type natriuretic peptide from individual human vascular endothelial cells. J Endocrinol, 175:225–232, 2002.
Fan, Bryan PM, and Antos LK et al. Downregulation does not mediate natriuretic peptide dependent desensitization of npr-a or npr-b: guanylyl cyclase-linked natriuretic peptide receptors do not internalize. Mol Pharmacol (printed online Sept 30, 2004), 2004.
Fan, Bryan, and Antos LK. Down-regulation does not mediate natriuretic peptideependent desensitization of natriuretic peptide receptor (npr)-a or npr-b. Guanylyl cyclase-linked natriuretic peptide receptors do not internalize. Mol Pharmacol, 67:1–10, 2005a.
Fan, PM Bryan, LK Antos, RJ Potthast, and LR Potter. Down- regulation does not mediate natriuretic peptide-dependent desensitization of natriuretic peptide receptor (npr)-a or npr-b: Guanylyl cyclase-linked natriuretic peptide receptors do not internalize. Mol Pharmacol, 67:174183, 2005b. 
Felker GM, Anstrom KJ, Adams KF, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2017; 318:713.
Felker GM, Whellan DJ. Inpatient Management of Heart Failure: Are We Shooting at the Right Target? Ann Intern Med 2017; 166:223.
Fellahi JL, Daccache G, Makroum Y, Massetti M, Gérard JL, Hanouz JL.  The Prognostic Value of B-Type Natriuretic Peptide After Cardiac Surgery: A Comparative Study Between Coronary Artery Bypass Graft Surgery and Aortic Valve Replacement.Journal of Cardiothoracic and Vascular Anesthesia 2012, 26(4):624-630.
Fellahi JL, Daccache G, Rubes D, Massetti M, Gérard JL, Hanouz JL.  Does Preoperative B-Type Natriuretic Peptide Better Predict Adverse Outcome and Prolonged Length of Stay Than the Standard European System for Cardiac Operative Risk Evaluation After Cardiac Surgery? Journal of Cardiothoracic and Vascular Anesthesia 2011, 25(2):256-262
Fonarow, Peacock, Phillips, et al, ADHERE Scientific Advisory Committee, and Investigators. Admission b-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol, 49:1943–50, 2007. 
Foote, Pearlman JD, and Siegel AH andYeo KT. Detection of exercise- induced ischemia by changes in b-type natriuretic peptide. J Am Coll Cardiol, 44:1980–1987, 2004.  
Fraser. Inherent biological variation and reference values. (Review) Clin Chem Lab Med, 42:758–764, 2004.
Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW.Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.Br J Pharmacol. 2008 Mar;153(5):947-55. Epub 2007 Dec 17.
Functions and Therapeutic Applications.  Handb Exp Pharmacol. 2009 ; (191): 341–366
Gaggin and James L Januzzi. Natriuretic peptides in heart failure syndrome. Clin Lab Med, 34:43–58, 2014. 
Gaggin and Januzzi. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta, 1832(12):2442–50, 2013. 
Galvani, Ferrini D, and Ottani T. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. (Review) Eur J Heart Fail, 6:327–333, 2004.
Gardner, F Ozalp, AJ Murday, SD Robb, and TA McDonagh. N- terminal prorain natriuretic peptide a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J, 24:1735–43, 2003.
Gharib and Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. (Review) Eur J Heart Fail, 4:235–242, 2002.
Giannessi, Andreassi MG, and Del Ry S et al. Possibility of age regulation of the natriuretic peptide c-receptor in human platelets. J Endocrinol Invest, 24:8–16, 2001.
Goetze. Biochemistry of pro-b-type natriuretic peptide-derived peptides the endocrine heart revisited. Clin Chem, 9:1503–1510, 2004a. 
Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Hernandez AF.  Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).  J Am Coll Cardiol. 2013 Sep;62(13):1177-83. Epub 2013 Jun 7.
Gyurko, Kuhlencordt, Fishman, and Huang OL. Modulation of mouse cardiac function in vivo by enos and anp. Am J Physiol, 278:H971– 981, 2000.
Hall. Nt-probnp: the mechanism behind the marker. J Card Fail, 11:S81–3, 2005.  Han and Hasin. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther, 17:41–52, 2003.
Hartmann, M Packer, AJ Coats, MB Fowler, H Krum, P Mohacsi, JL Rouleau, M Tendera, A Castaigne, SD Anker, I Amann-Zalan, S Hoersch, and HA Katus. Prognostic impact of plasma n-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (copernicus) trial. Circulation, 110:1780–6, 2004.
Hedberg, Lonnberg I, and Jonason T et al. Electrocardiogram and b- type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a populationased sample of 75-year-old men and women. Am Heart J, 148:524–529, 2004.
Heidenreich, Gubens MA, and Fonarow GC et al. Cost-effectiveness of screening with b-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol, 43: 1019–1026, 2004.
Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr.  Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49(5):1114. Epub 2007 Mar 19.
Holtwick, M Gotthardt, B Skryabin, M Steinmetz, R Potthast, B Zetsche, RE Hammer, J Herz, and M Kuhn. Smooth muscle- selective deletion of guanylyl cyclase-a prevents the acute but not chronic effects of anp on blood pressure. Proc Natl Acad Sci U S A, 99:7142–7147, 2002.
Houben, van der Zander, and de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man physiology and pharmacology. Fundam Clin Pharmacol, 19:411–419, 2005.
Hsich, Grau-Sepulveda, Hernandez, and et al. Relationship between sex, ejection fraction, and b-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the get with the guideline-heart failure registry.Am Heart J, 166:1063-71,2013.
Hutcheon, Gillespie ND, Struthers AD, and McMurdo ME. B-type natriuretic peptide in the diagnosis of elderly day hospital patients. Age Ageing, 31:295–301, 2002. 
Iwanaga, I Nishi, S Furuichi, T Noguchi, K Sase, and Y Kihara. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Journal of American College of Cardiology, 47:742–8, 2006.
James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108:275.
Januzzi, CA Camargo, S Anwaruddin, AL Baggish, AA Chen, DG Krauser, R Tung, R Cameron, JT Nagurney, CU Chae, DM Lloyd-Jones, DF Brown, S Foranelanson, PM Sluss, E Lee- Lewandrowski, and KB Lewandrowski. The n-terminal pro-bnp investigation of dyspnea in the emergency department (pride) study. Am J Cardiol, 95:948–54, 2005.
Januzzi, Sakhuja, O’Donoghue, and et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med, 166:315–20, 2006a.
Januzzi, van Kimmenade, Lainchbury, Bayes-Genis, Ordonez-Llanos, Santalo-Bel, Pinto, and Richards. Nt-probnp testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of nt-probnp (icon) study. Eur Heart J, 27:330–7, 2006b.
Jogia PM, Kakoff M, Sleigh JW, Bertinelli A, LaPine M, Richards AM, Devlin G.  NTproBNP  secretion and clinical endpoints in cardiac surgery intensive care patients. Anaesth Intensive Care 2007, 35:363-369.
Joubert, Labrecque, and De Lean. Reduced activity of the npr-a kinase triggers dephosphorylation and homologous desensitization of the receptor. Biochemistry, 40:11096–11105, 2001.
Jourdain, Jondeau, and Funck et al. Plasma brain natriuretic peptide- guided therapy to improve outcome in heart failure: the stars-bnp multicenter study. J Am Coll Cardiol, 49, 2007.
Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009; 54:1599.
Kazanegra, V Cheng, and A Garcia et al. A rapid test for b-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail, 7:21–9, 2001.
Kerbaul F, Collart F, Giorgi R, Oddoze C, Lejeune PJ, Guidon C, Caus T, Bellezza M, Gouin F.  Increased plasma levels of pro=brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery.  Intensive Care Med 2004, 30:1799–1806
Knowles, G Esposito, L Mao, JR Hagaman, JE Fox, O Smithies, HA Rockman, and N Maeda. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor adeficient mice. J Clin Invest, 107:975–984, 2001.
Komajda, Carson, and Hetzel et al. Factors associated with outcome in heart failure with preserved ejection fraction findings from the irbesartan in heart failure with preserved ejection fraction study (i- preserve). Circ Heart Fail, 4:27–35, 2011. 
Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103.
Kragelund C, Grønning B, Køber L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666.
Kragelund, Gronning B, and Kober L et al. N-terminal pro-b-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med, 352:666– 75, 2005.
Kraigher-Krainer, Shah, and Gupta et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol, 63:447–56, 2014. 
Kuhn, Voss M, and Mitko D et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end- tage heart failure. Cardiovasc Res, 64:308–314, 2004.
Lainchbury, RW Troughton, and KM Strangman et al. N-terminal pro-b-type natriuretic peptide-guided treatment for chronic heart failure: results from the battlescarred (nt-probnp-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol, 55:53–60, 2009.
Langenickel, J Buttgereit, I Pagel-Langenickel, M Lindner, J Monti, K Beuerlein, N Al-Saadi, R Plehm, E Popova, J Tank, R Dietz, R Willenbrock, and M Bader. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor b. Proc Natl Acad Sci U S A, 103:4735–4740, 2006.
Latini, Masson S, De Angelis N, and Anand I. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. (Review) J Card Fail, 8:288–299, 2002.
Latini, Masson, and Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in val-heft. Eur Heart J, 25:292–299, 2004.
Leszek P, Klisiewicz A, Janas J, et al. Determinants of the reduction in B-type natriuretic peptide after mitral valve replacement in patients with rheumatic mitral stenosis. Clin Physiol Funct Imaging 2010; 30:473.
Lewis, MM Salem, GM Chertow, LS Weisberg, F McGrew, TC Marbury, and RL Allgren. Atrial natriuretic factor in oliguric acute renal failure; anaritide acute renal failure study group. Am J Kidney Dis, 36:767–774, 2000.
Liu H, Wang C, Liu L, Zhuang Y, Zhang Y.  Perioperative application of N-terminal pro-brain natriuretic peptide in patients undergoing cardiac surgery.  Journal of Cardiothoracic Surgery 2013, 8:1-5.
Lurati Buse GA, Koller MT, Burkhart C, et al. The predictive value of preoperative natriuretic peptide concentrations in adults undergoing surgery: a systematic review and meta-analysis. Anesth Analg 2011; 112:1019.
Maisel and Nicholas Wettersten. Natriuretic peptides in heart failure. Atrial and b-type natriuretic peptides. Heart Failure Clin, 14:13–25, 2018.  
Maisel, Hollander, Guss, and Rapid Emergency Department Heart Failure Outpatient Trial Investigators. et al. Primary results of the rapid emergency department heart failure outpatient trial (redhot). a multicenter study of b-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol, 44:1328–33, 2004. 
Maisel, J McCord, RM Nowak, JE Hollander, AH Wu, P Duc, T Omland, AB Storrow, P Krishnaswamy, WT Abraham, P Clopton, G Steg, MC Aumont, A Westheim, CW Knudsen, A Perez, R Kamin, R Kazanegra, HC Herrmann, and PA McCullough. Bed- side b-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: Results from the breathing not properly multinational study. J Am Coll Cardiol, 41: 2010–7, 2003. 
Maisel, P Krishnaswamy, RM Nowak, J McCord, JE Hollander, P Duc, T Omland, AB Storrow, WT Abraham, AH Wu, P Clopton, PG Steg, A Westheim, CW Knudsen, A Perez, R Kazanegra, HC Herrmann, and Investigators of Breathing Not Properly Multi- national Study. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 347:161–7, 2002.
Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, Heitjan DF, Katz SD.  Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94(12):3184.
Masson, R Latini, IS Anand, T Vago, L Angelici, S Barlera, ED Missov, A Clerico, G Tognoni, and JN Cohn (on behalf of the Val-HeFT Investigators). Direct comparison of b-type natriuretic peptide (bnp) and amino-terminal probnp in a larger population of patients with chronic and symptomatic heart failure: the valsartan heart failure data. Clin Chem, 52:1528–1538, 2006. 
May, Horne, Levy, and et al. Validation of the seattle heart failure model in a community-based heart failure population and enhancement by adding b-type natriuretic peptide. Am J Cardiol, 100:697– 700, 2007.
McKie and JC Burnett. Nt-probnp: the gold standard biomarker in heart failure. J Am Coll Cardiol, 68:2437–9, 2016. 
McMurray, M Packer, and AS Desai. AD Michaels, K Chatterjee, and T Dearco. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail, 11:425–431, 2005.
McQuade CN, Mizus M, Wald JW, et al. Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure: A Systematic Review. Ann Intern Med 2017; 166:180.
Mills, TH LeJemtel, DP Horton, C Liang, R Lang, MA Silver, C Lui, and K Chatterjee. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial; natrecor study group. J Am Coll Cardiol, 34:155–162, 1999.
Moe, J Howlett, Januzzi et al, and Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-b-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the canadian prospective randomized multicenter improve-chf study. Circulation, 115: 3103–10, 2007.
Morimoto, Hayashino Y, and Shimbo T et al. Is b-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol, 96:177–181, 2004. 
Morita, Yasue, and Yoshimura et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation, 88:82–91, 1993. 
Mueller, A Scholer, and K Laule-Kilian et al. Use of b-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med, 350:647–54, 2004.
Nakamura, Sakai T, and Osawa M et al. Comparison of positive cases for b-type natriuretic peptide and ecg testing for identification of precursor forms of heart failure in an elderly population. Int Heart J, 46:477–487, 2005.
Nakanishi, Saito, and Kishimoto. Role of natriuretic peptide receptor guanylyl cyclase-a in myocardial infarction evaluated using genetically engineered mice. Hypertension, 46:1–7, 2005.
Nakayama. The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J, 52:11–21, 2005.
Ndrepepa G, Braun S, Niemöller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 2005; 112:2102.
Ng, Geeranavor, Jennings, Loki, and O’Brien. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci, 106:129–133, 2004. 
Ng, Loke I, and Davies JE et al. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail, 5:775–782, 2003.
Nielsen, McDonagh TA, Robb SD, and Dargie HJ. Retrospective analysis of the costeffectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol, 41:113–120, 2003.
Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK.  Atrial natriuretic peptide for preventing and treating acute kidney injury.  Cochrane Database Syst Rev. 2009.
Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(2):261. Epub 2008 Dec 10.
O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Wilson WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure.  N Engl J Med. 2011;365(1):32.
Ogawa, Qiu, Ogata, and Risono KS. Crystal structure of hormone- bound atrial natriuretic peptide receptor extracellular domain rotation mechanism for transmembrane signal transduction. J Biol Chem, 279:28625–28631, 2004.
Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ, PARADIGM-HF Investigators and Committees. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.Circ Heart Fail. 2016;9(9) 
Olney, H Bukulmez, CF Bartels, TC Prickett, EA Espiner, LR Potter, and ML Warman. Heterozygous mutations in natriuretic peptide receptor-b (npr2) are associated with short stature. J Clin Endocrinol Metab, 91:1229–1232, 2006. 
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.Lancet Diabetes Endocrinol. 2018;6(7):547. Epub 2018 Apr 13.
Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, KozanÖ, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan;131(1):54-61. Epub 2014 Nov 17.
Packer, McMurray, PARADIGM-HF Investigators Desai et al, and Coordinators. Angiotensin receptor neprilysin inhibition comparedwith enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation, 131:54–61, 2015.
Pandey. Biology of natriuretic peptides and their receptors. Peptides, 26:901–932, 2005.
Pandey. Intracellular trafficking and metabolic turnover of ligand- bound guanylyl cyclase/atrial natriuretic peptide receptor-a into subcellular compartments. Mol Cell Biochem, 230:6172, 2002. 
Pankow, Y Wang, F Gembardt, E Krause, X Sun, G Krause, HP Schultheiss, WE Siems, and T Walther. Successive action of meprin a and neprilysin catabolizes b- ype natriuretic peptide. Circ Res, 101:875–882, 2007.
Panteghini and Clerico. Understanding the clinical biochemistry of n-terminal pro-b- ype natriuretic peptide: the prerequisite for its optimal clinical use. (Review) Clin Lab, 50:325–331, 2004.
Panteghini, Cuccia C, and Bonetti G et al. Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. Clin Chem Lab Med, 41:164– 68, 2003.
Patel, ML Valencik, AM Pritchett, JC Burnett, JA McDonald, and MM Redfield. Cardiac-specific attenuation of natriuretic peptide a receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol, 289:H777H784, 2005.
Perras, Schultes, and Behn. Intranasal atrial natriuretic peptide acts as central nervous inhibitor of the hypothalamo-pituitary-adrenal stress system in humans. J Clin Endocrinol Metab, 89:4642–4648, 2004.
Pfisterer, P Buser, and H Rickli et al. Bnp-guided vs symptom- guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (time- chf) randomized trial. JAMA, 301:383– 2, 2009.
Porapakkham, Zimmet, Billah, and et al. B-type natriuretic peptide- guided heart failure therapy: a meta-analysis. Arch Intern Med, 170: 507–14, 2010. 
Potter, Andrea R. Yoder, Darcy R. Flora, Laura K. Antos, and Deborah M. Dickey. Natriuretic Peptides: Their Structures, Receptors, Physiologic
Potter. natriuretic peptide metabolism, clearance and degradation. FEBS J, 278:1808–17, 2011.
Potthast, SE Abbey-Hosch, LK Antos, JS Marchant, M Kuhn, and LR Potter. Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-b/guanylyl cyclase-b. J Biol Chem, 279: 48513–48519, 2004.
Qian, Haruno, and Asada. Local expression of c-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res, 91: 1063–1069, 2002.
Quynh Troung, James Bayley, Udo Hoffman, Fabian Bamberg, Christopher Schlett, John Nagurney, Wolfgang Koenig, and James Januzzi. Multi-marker strategy of natriuretic peptide with eiter conventional or high-sensitivity troponin-t for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the romicat trial. Am Heart J, 163(6):972–9, 2012. 
Rahman, GE Kim, AS Mathew, CA Goldberg, R Allgren, RW Schrier, and JD Conger. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int, 45:1731–1738, 1994.
Ray, Arthaud M, and Lefort Y et al. Usefulness of b-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med, 30:2230–2236, 2004. 
Richards AM. N-terminal b-type natriuretic peptide in heart failure. Heart Failure Clin, 14:27–39, 2018. 
Richards and Troughton. Nt-probnp in heart failure: therapy decisions and monitoring. (Review) Eur J Heart Fail, 6:351–354, 2004. 
Richards, Di Somma, and Mueller et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the biomarkers in acute heart failure (bach) study. JACC Heart Fail, 1:192–9, 2013.
Rodseth RN, Biccard BM, Le Manach Y, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol 2014; 63:170.
Rodseth RN. B-type natriuretic peptide – a diagnostic breakthrough in perioperative cardiac risk? Anasthesia. 2009, 64:165-78
Rose and WR Giles. Natriuretic peptide c receptor signalling in the heart and vasculature. J Physiol, 586:353–366, 2008.
Sabatine, Morrow DA, and de Lemos JA et al. TIMI Study Group. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol, 44:1988–1995, 2004.
Sabrane, MN Kruse, L Fabritz, B Zetsche, D Mitko, BV Skryabin, M Zwiener, HA Baba, M Yanagisawa, and M Kuhn. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest, 115:1666–1674, 2005.
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.  JAMA. 2005;293(15):1900.
Sandri, Salvatici M, and Cardinale D et al. N-terminal pro-b-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem, 51:1405–1410, 2005.
Sarzani, Strazzullo P, and Salvi F et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res, 12:351–356, 2004.
Schachner T, Wiedemann D, Fetz H, Laufer G, Kocher A, Bonaros N.  Influence of preoperative serum N-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients.  Clinics 2010;65(12):1239-1245
Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47:552.
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333. Epub 2017 Mar 18.
Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, KozanÖ, Dukat A, Lefkowitz MP, McMurray JJ. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.Circ Heart Fail. 2016.
Squire, Orn S, and Ng LL et al. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to orognosis: an optimaal substudy. J Card Fail, 11:492–497, 2005.
Suzuki T,Yamazaki T, and Yazaki Y. The role of natriuretic peptides in the cardiovascular system. Cardiovascular Research, 51:489–494, 2001.
Sward, F Valsson, J Sellgren, and SE Ricksten. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. Intensive Care Med, 31:79–85, 2005.
Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE.  Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial.  Crit Care Med. 2004;32(6):1310. 
Takeda, Fukutomi, and Suzuki et al. Effects of carvedilol on plasma b-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol, 94: 448–453, 2004.
Tamura, Y Ogawa, H Chusho, K Nakamura, K Nakao, M Suda, M Kasahara, R Hashimoto, G Katsuura, M Mukoyama, H Itoh, Y Saito, I Tanaka, H Otani, and M Katsuki. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A, 97:4239–4244, 2000.
Thay-Hsiung C, Ching-Ling L, Joseph JS, James YS, Chung-Huo c, Mei-Ling C and Chih-Hui C.  Plasma B-type natriuretic peptide in predicting outcomes of elective coronary artery bypass surgery.  Kaohsiung journal of medical sciences. 2013, 29:254-258
Troughton and Richards. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging, 2:216–25, 2009.
Troughton, CM Frampton, TG Yandle, EA Espiner, MG Nicholls, and AM Richards. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (n-bnp) concentrations. Lancet, 355:1126–30, 2000.
Troughton, CM Frampton, and HP Brunner-La Rocca et al. Effect of b-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J, 35:1559–67, 2014.
Tsuji and T Kunieda. A loss-of-function mutation in natriuretic peptide receptor 2 (npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem, 280:1428814292, 2005. 
Ueda, Yokouchi M, and Suzuki T et al. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med, 114:266–270, 2003.
Valle, Aspromonte N, and Barro S et al. The nt-probnp assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail, 7:542–551, 2005.
Vasan, Benjamin, and Larson et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA, 288:1252–1259, 2002.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539. Epub 2018 Nov 11.
Vesely. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol, 285:F167–177, 2003. 
Vieira, M Gao, LN Nikonova, and T Maack. Molecular and cellular physiology of the dissociation of atrial natriuretic peptide from guanylyl cyclase a receptors. J Biol Chem, 276:3643836445, 2001. 
Vollmar and Kiemer AK. Immunomodulatory and cytoprotective function of atrial natriuretic peptide. Crit Rev Immunol, 21:473–485, 2001.
Vollmar. The role of atrial natriuretic peptide in the immune system. Peptides, 26:1086–1094, 2005.
Volpe, M Carnovali, and V Mastromarino. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci, 130:57–77, 2016.
Walther, Klostermann, and Hering-Walther. Fibrosis rather than blood pressure determines cardiac bnp expression in mice. Regul Pept, 116:95–100, 2003.
Wang, Larson, Levy, and et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med, 350, 2004.
Wang, MC deWaard, A Sterner-Kock, H Stepan, HP Schultheiss, DJ Duncker, and T Walther. Cardiomyocyte-restricted overexpression of c-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail, 9: 548–557, 2007.
Waschek. Developmental actions of natriuretic peptides in the brain and skeleton. Cell Mol Life Sci, 61:2332–2342, 2004.
Williams, Ng, and O’Brien et al. Comparison of plasma n-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. Am J Cardiol, 93: 1560–1561, 2004.
Witteles, D Kao, D Christopherson, K Matsuda, RH Vagelos, D Schreiber, and MB Fowler. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol, 50:1835–1840, 2007.
Wiviott, de Lemos JA, and Morrow DA. Pathophysiology, prognostic significance and clinical utility of b-type natriuretic peptide in acute coronary syndromes. (Review) Clin Chim Acta, 346:119–128, 2004. 
Woodard, Rosado, and Brown. Expression and control of c-type natriuretic peptide in rat vascular smooth muscle cells. Am J Physiol Reg Int Comp Physiol, 282:R156–165, 2002.
Wright, Doughty, and Pearl et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol, 42:1793– 1800, 2003.
Wu, F Wu, J Pan, J Morser, and Q Wu. Furin-mediated processing of pro-c-type natriuretic peptide. J Biol Chem, 278:25847–25852, 2003b. 
Wu, Smith A, and Wieczorek S et al. Biological variation for n-terminal proand btype natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol, 92:628–631, 2003a.
Yasoda, Y Komatsu, H Chusho, T Miyazawa, A Ozasa, M Miura, T Kurihara, T Rogi, S Tanaka, M Suda, N Tamura, Y Ogawa, and K Nakao. Overexpression of cnp in chondrocytes rescues achondroplasia through a mapk-dependent pathway. Nat Med, 10:80–86, 2004.
Young, William T. Abraham,  Lynne Warner Stevenson, Darlene P. Horton, Robert C. Bourge; Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF).  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.  JAMA. 2002;287(12):1531.
Zethelius B, Berglud L, Sundstrom J, Ingelsson E, Basu S, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.  N Eng J Med. 2008, 358:2107-2116
Zile, Claggert, Prescott, and et al. Prognostic implications of changes in n-terminal pro-b-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol, 68:2425–36, 2016. 
de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014.
